AGI-6780
98%
- Product Code: 135396
CAS:
1432660-47-3
| Molecular Weight: | 481.51 g./mol | Molecular Formula: | C₂₁H₁₈F₃N₃O₃S₂ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2~8℃, dry, sealed |
Product Description:
AGI-6780 is a selective small molecule inhibitor primarily used in research settings to target mutant forms of the isocitrate dehydrogenase 2 (IDH2) enzyme, particularly the R140Q mutation. It is employed to study the biological effects of blocking the production of the oncometabolite 2-hydroxyglutarate (2-HG), which accumulates in certain cancers and contributes to dysregulated cell differentiation.
In preclinical models, AGI-6780 has demonstrated the ability to reverse aberrant epigenetic modifications and promote differentiation of immature myeloid cells, making it a valuable tool for investigating acute myeloid leukemia (AML) and other IDH2-mutant malignancies. Its application supports the development of targeted therapies by providing insights into the reversibility of oncogenic metabolic effects and the potential for epigenetic reprogramming in cancer treatment.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 5mg | 10-20 days | $116.85 |
+
-
|
| 10mg | 10-20 days | $153.85 |
+
-
|
| 50mg | 10-20 days | $242.03 |
+
-
|
| 250mg | 10-20 days | $658.57 |
+
-
|
AGI-6780
AGI-6780 is a selective small molecule inhibitor primarily used in research settings to target mutant forms of the isocitrate dehydrogenase 2 (IDH2) enzyme, particularly the R140Q mutation. It is employed to study the biological effects of blocking the production of the oncometabolite 2-hydroxyglutarate (2-HG), which accumulates in certain cancers and contributes to dysregulated cell differentiation.
In preclinical models, AGI-6780 has demonstrated the ability to reverse aberrant epigenetic modifications and promote differentiation of immature myeloid cells, making it a valuable tool for investigating acute myeloid leukemia (AML) and other IDH2-mutant malignancies. Its application supports the development of targeted therapies by providing insights into the reversibility of oncogenic metabolic effects and the potential for epigenetic reprogramming in cancer treatment.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
$0.00
$0.00
Total :